Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Pareesh Phulkar
pareesh@coherentmarketinsights.com
www.coherentmarketinsights.com/

Bookmark and Share
Drug Abuse Treatment Market - Integrate new technologies with effectiveness 2026
Frequent product launches, approvals, and robust pipeline of novel products are expected to be the major driver for growth of the global drug abuse treatment market over forecast period.


Drug Abuse Treatment Mark
BriefingWire.com, 9/13/2019 - Frequent product launches, approvals, and robust pipeline of novel products are expected to be the major driver for growth of the global drug abuse treatment market over forecast period. For instance, in April 2018, Lil' Drug Store Products Inc. launched its Nicotac brand nicotine gum in the market. Lil' Drug Store Products Inc. has launched its Nicotac in two nicotine strengths (2MG and 4MG nicotine polarcrilex).

Furthermore, the increasing prevalence of drug abuse is expected to increase the demand for its treatment drugs which in turn is expected to fuel global drug abuse treatment market growth. For instance, according to the data published by World Health Organization (WHO) in 2018, around 7 million people die worldwide annually due to tobacco abuse.

Get PDF Brochure of This Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/2011

For instance, in 2015, Mylan N.V. launched its new drugs Disulfiram Tablets USP, 250 mg and 500 mg in the U.S. market, drugs Disulfiram Tablets USP is a generic version of Odyssey Pharmaceutical's Antabuse. In 2017, Glenmark Pharmaceuticals launched its new nicotine replacement therapy namely Kwitz in India. Kwitz is a nicotine gum and is available in two variants Kwitz 2 mg and Kwitz 4 mg. Kwitz 2 mg is for the smokers having less than 20 cigarettes per day and Kwitz 4 mg is for those who smoke more than 20 cigarettes per day.

In April 2018, Lil' Drug Store Products Inc. launched its Nicotac brand nicotine gum in market. Lil' Drug Store Products Inc. has launched its Nicotac in two nicotine strengths (2 mg and 4 mg nicotine polarcrilex). In 2017, Cipla Health, an arm of Cipla Limited launched a new Nicotex Nicotine Patches. Nicotex Nicotine Patches are skin/transdermal patches, which helps to quit smoking in 12 months. Company has launched its patches in 3 strengths 21 mg, 14 mg, and 7 mg. 21 mg patch is for one who smoke more than 20 cigarette a day, 14 mg is for those who smoke less that 20 cigarette a day

Key players operating in the drug abuse treatment market include Cipla Limited, Glenmark Pharmaceuticals, Pfizer Inc., Mylan N.V., Odyssey Pharmaceuticals Inc., Lil' Drug Store Products Inc., Indivior Plc., Dr. Reddy's Laboratories, Teva Pharmaceutical Industries Ltd., and British American Tobacco Plc.

Browse more detail information about: https://www.coherentmarketinsights.com/market-insight/drug-abuse-treatment-market-2011

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2019 Proserve Technology, Inc.